<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00654589</url>
  </required_header>
  <id_info>
    <org_study_id>CICL670ADE02</org_study_id>
    <nct_id>NCT00654589</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron Overload</brief_title>
  <official_title>A One-year, Open-label, Single Arm, Multi-center Trial Evaluating the Efficacy and Safety of Oral ICL670 (20 mg/kg/d) in Patients Three to Six Months After Allogeneic Hematopoietic Cell Transplantation in Whom Iron Overload is Present</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effects of iron chelation using deferasirox
      in patients who show signs of iron overload after an allogeneic stem cell transplantation The
      iron overload must be due to blood transfusions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess iron chelation by comparing serum ferritin values at baseline vs. 52 weeks of treatment with deferasirox</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the relationship between serum ferritin, transferrin (TRF) and transferrin saturation during the whole study.</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Iron Overload</condition>
  <arm_group>
    <arm_group_label>deferasirox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferasirox</intervention_name>
    <arm_group_label>deferasirox</arm_group_label>
    <other_name>ICL670</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Transfusional iron overload three to six months after HCT with no evidence of active
             inflammation

          2. History of at least 20 units of red blood cell transfusions or 100mL/kg of prepacked
             red blood cells (PRBCs).

          3. Patients of either gender and age ≥ 18 years.

          4. Female patients who have reached menarche and who are sexually active must use
             double-barrier contraception, oral contraceptive plus barrier contraception , or must
             have undergone clinically documented total hysterectomy and/or ovariectomy, or tubal
             ligation or be postmenopausal defined by amenorrhea for at least 12 months.

        Exclusion criteria:

          1. Non-transfusion related iron overload

          2. Active malignancy

          3. Known active viral hepatitis or known HIV positiveness

          4. Mean levels of alanine aminotransferase (ALT) &gt; 5x ULN

          5. Treatment with any iron chelator after transplantation

          6. Uncontrolled systemic hypertension

          7. Serum creatinine &gt; 1.5 ULN and/or serum creatinine clearance &lt; 60 ml/min

          8. History of nephrotic syndrome.

          9. Previous history of clinically relevant ocular or auditory toxicity related to iron
             chelation.

         10. Systemic diseases (cardiovascular, renal, hepatic, etc.) which would prevent the
             patient from undergoing study treatment

         11. Pregnant or breast feeding patients.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmeceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=7904</url>
    <description>CICL670ADE02 Results at Novartis Clinical Trials Results Website</description>
  </link>
  <results_reference>
    <citation>Jaekel N, Lieder K, Albrecht S, Leismann O, Hubert K, Bug G, Kröger N, Platzbecker U, Stadler M, de Haas K, Altamura S, Muckenthaler MU, Niederwieser D, Al-Ali HK. Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2016 Jan;51(1):89-95. doi: 10.1038/bmt.2015.204. Epub 2015 Sep 14.</citation>
    <PMID>26367238</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2008</study_first_submitted>
  <study_first_submitted_qc>April 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2008</study_first_posted>
  <last_update_submitted>November 16, 2016</last_update_submitted>
  <last_update_submitted_qc>November 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hematopoietic stem cell transplantation</keyword>
  <keyword>HCT</keyword>
  <keyword>iron overload</keyword>
  <keyword>chelators</keyword>
  <keyword>ICL670</keyword>
  <keyword>deferasirox</keyword>
  <keyword>serum ferritin</keyword>
  <keyword>LIC</keyword>
  <keyword>transfusional hemosiderosis</keyword>
  <keyword>blood transfusions</keyword>
  <keyword>adults</keyword>
  <keyword>iron chelation</keyword>
  <keyword>3-6 months</keyword>
  <keyword>allogeneic hematopoietic stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron Overload</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Deferasirox</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

